Compare Humana Inc (HUM) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Target Corporation — how do they compare? Humana Inc trades at $374.25 (market cap $46.31B), while Target Corporation trades at $151.87 (market cap $69.05B). The key difference: Target Corporation is the larger of the two by market cap, and Target Corporation pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| HUM | TGT | |
|---|---|---|
Market Cap | $46.31B | $69.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $409.42 | $152.09 |
52-Week Low | $163.67 | $83.68 |
Enterprise Value | $53.67B | $84.34B |
Dividend Yield | 0.92% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
Target (TGT) trades at $149.70, up 1.77% today and near its 52-week high of $151.23, with a bullish technical trend and strong recent earnings beats. The stock shows solid fundamentals with a P/E of 19.78 and net income margin of 3.24%, supported by positive cash flow trends. Recent analyst upgrades and media coverage highlight optimism around the retailer's turnaround and upcoming Q2 results.
The outlook for TGT is positive, driven by consistent earnings outperformance and improving cash flow, though risks include competitive retail pressures and potential margin compression. With a consensus price target of $146.19 and bullish analyst sentiment, the stock offers upside potential, but investors should monitor consumer spending trends and quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
